2023-12-27 13:25:53 ET
Calliditas Therapeutics ( NASDAQ: CALT ) said Friday it has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management LP.
Proceeds from the loan will primarily be utilized for full repayment of the company's existing 68 million Euro loan with Kreos Capital.
More on Calliditas Therapeutics
- Calliditas Therapeutics: Undervalued Rare Disease Commercial Stage Biotech (Maintaining Buy)
- Callidatas stock jumps 15% after FDA grants full approval for Tarpeyo
- Calliditas partner wins China nod for kidney disease therapy
- Seeking Alpha’s Quant Rating on Calliditas Therapeutics
- Historical earnings data for Calliditas Therapeutics
For further details see:
Calliditas refinances existing term loan with EUR 92M senior secured facility